Le SIDA au Ghana (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa

Identifieur interne : 000E74 ( Main/Exploration ); précédent : 000E73; suivant : 000E75

Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa

Auteurs : Chitra Akileswaran [États-Unis] ; Mark N. Lurie [États-Unis] ; Timothy P. Flanigan [États-Unis] ; Kenneth H. Mayer [États-Unis]

Source :

RBID : ISTEX:A1E0411A67D7CA0128D1F9CE5FAE00ABEBAC4C6F

Abstract

Background. Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs. Methods. We searched academic databases and recent conference abstracts for studies, and we included all studies that documented patients receiving HAART in Africa. In particular, we examined studies for such program features as type of regimen and frequency of monitoring, in addition to evaluations of patient outcomes. Results. Twenty-eight articles and abstracts involving studies from 14 African countries were reviewed. Overall, 6052 patients (96.4%) were receiving HAART, mainly consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. All studies reported an increase in mean and median CD4 cell counts, and a median of 73% of patients achieved undetectable viral loads by the end of the study period. Monitoring of CD4 cell count and viral load at 6-month intervals was completed by all studies. The median weight gained was 5.0 kg, and the median mortality rate was 7.4% (range, 0%–27%). Six studies reported that 68%–99% of patients took >95% of medications. Five studies measured drug resistance; most cases of resistance involved NRTIs. Conclusions. Many studies reported positive health outcomes, including high levels of treatment adherence that were comparable to those of industrialized countries. Regimens and monitoring means based on WHO guidelines were implemented—and at times, exceeded—in all studies reviewed. We found compelling evidence that HAART can be feasibly administered in resource-limited settings.

Url:
DOI: 10.1086/431482


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa</title>
<author>
<name sortKey="Akileswaran, Chitra" sort="Akileswaran, Chitra" uniqKey="Akileswaran C" first="Chitra" last="Akileswaran">Chitra Akileswaran</name>
</author>
<author>
<name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name>
</author>
<author>
<name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P." last="Flanigan">Timothy P. Flanigan</name>
</author>
<author>
<name sortKey="Mayer, Kenneth H" sort="Mayer, Kenneth H" uniqKey="Mayer K" first="Kenneth H." last="Mayer">Kenneth H. Mayer</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A1E0411A67D7CA0128D1F9CE5FAE00ABEBAC4C6F</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1086/431482</idno>
<idno type="url">https://api.istex.fr/document/A1E0411A67D7CA0128D1F9CE5FAE00ABEBAC4C6F/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000931</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000931</idno>
<idno type="wicri:Area/Istex/Curation">000931</idno>
<idno type="wicri:Area/Istex/Checkpoint">000470</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000470</idno>
<idno type="wicri:doubleKey">1058-4838:2005:Akileswaran C:lessons:learned:from</idno>
<idno type="wicri:Area/Main/Merge">000F18</idno>
<idno type="wicri:Area/Main/Curation">000E74</idno>
<idno type="wicri:Area/Main/Exploration">000E74</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa</title>
<author>
<name sortKey="Akileswaran, Chitra" sort="Akileswaran, Chitra" uniqKey="Akileswaran C" first="Chitra" last="Akileswaran">Chitra Akileswaran</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>Brown University Medical School</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>Brown University Medical School</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>The Miriam Hospital, Providence</wicri:cityArea>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P." last="Flanigan">Timothy P. Flanigan</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>Brown University Medical School</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>The Miriam Hospital, Providence</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Mayer, Kenneth H" sort="Mayer, Kenneth H" uniqKey="Mayer K" first="Kenneth H." last="Mayer">Kenneth H. Mayer</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>Brown University Medical School</wicri:cityArea>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Rhode Island</region>
</placeName>
<wicri:cityArea>The Miriam Hospital, Providence</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Clinical Infectious Diseases</title>
<title level="j" type="abbrev">Clinical Infectious Diseases</title>
<idno type="ISSN">1058-4838</idno>
<idno type="eISSN">1537-6591</idno>
<imprint>
<publisher>The University of Chicago Press</publisher>
<date type="published" when="2005-08-01">2005-08-01</date>
<biblScope unit="volume">41</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="376">376</biblScope>
<biblScope unit="page" to="385">385</biblScope>
</imprint>
<idno type="ISSN">1058-4838</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1058-4838</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Background. Because antiretrovirals are becoming increasingly available in developing countries, we reviewed the findings of studies that have documented highly active antiretroviral therapy (HAART) use in Africa to identify lessons learned. With the World Health Organization (WHO) guidelines used as a frame of reference, we assessed the feasibility of implementing such programs in Africa. Moreover, clinical and laboratory outcomes were compiled to determine the effectiveness of HAART programs. Methods. We searched academic databases and recent conference abstracts for studies, and we included all studies that documented patients receiving HAART in Africa. In particular, we examined studies for such program features as type of regimen and frequency of monitoring, in addition to evaluations of patient outcomes. Results. Twenty-eight articles and abstracts involving studies from 14 African countries were reviewed. Overall, 6052 patients (96.4%) were receiving HAART, mainly consisting of 2 nucleoside reverse-transcriptase inhibitors (NRTIs) and 1 nonnucleoside reverse-transcriptase inhibitor. All studies reported an increase in mean and median CD4 cell counts, and a median of 73% of patients achieved undetectable viral loads by the end of the study period. Monitoring of CD4 cell count and viral load at 6-month intervals was completed by all studies. The median weight gained was 5.0 kg, and the median mortality rate was 7.4% (range, 0%–27%). Six studies reported that 68%–99% of patients took >95% of medications. Five studies measured drug resistance; most cases of resistance involved NRTIs. Conclusions. Many studies reported positive health outcomes, including high levels of treatment adherence that were comparable to those of industrialized countries. Regimens and monitoring means based on WHO guidelines were implemented—and at times, exceeded—in all studies reviewed. We found compelling evidence that HAART can be feasibly administered in resource-limited settings.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Rhode Island</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Rhode Island">
<name sortKey="Akileswaran, Chitra" sort="Akileswaran, Chitra" uniqKey="Akileswaran C" first="Chitra" last="Akileswaran">Chitra Akileswaran</name>
</region>
<name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P." last="Flanigan">Timothy P. Flanigan</name>
<name sortKey="Flanigan, Timothy P" sort="Flanigan, Timothy P" uniqKey="Flanigan T" first="Timothy P." last="Flanigan">Timothy P. Flanigan</name>
<name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name>
<name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name>
<name sortKey="Lurie, Mark N" sort="Lurie, Mark N" uniqKey="Lurie M" first="Mark N." last="Lurie">Mark N. Lurie</name>
<name sortKey="Mayer, Kenneth H" sort="Mayer, Kenneth H" uniqKey="Mayer K" first="Kenneth H." last="Mayer">Kenneth H. Mayer</name>
<name sortKey="Mayer, Kenneth H" sort="Mayer, Kenneth H" uniqKey="Mayer K" first="Kenneth H." last="Mayer">Kenneth H. Mayer</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E74 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E74 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:A1E0411A67D7CA0128D1F9CE5FAE00ABEBAC4C6F
   |texte=   Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024